226320.KO It's Skin Co Ltd
- Market cap
- KRW 189B
- P/E
- 5.8x
- P/B
- 0.46x
- ROE
- 9.5%
- Dividend yield
- 5.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 226320.KO undervalued?
Graham number226320.KO trades 65.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
It's Skin Co Ltd fundamental analysis
No fundamental analysis for It's Skin Co Ltd yet.
It's Skin Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About It's Skin Co Ltd
It'S Hanbul Co., Ltd. develops, manufactures, and sells cosmetics in South Korea and internationally. It offers skin care and makeup products; amino acid toners and ampoules; cleansers, moisturizers, and highlighters; skin hydration solutions; and deodorants under the IT'S SKIN, Flamel MD, Dixionist, Chasin' Rabbits, ICS, ATOPALM, Real Barrier, Derma:B, and ZEROID brands. The company was formerly known as It'S SKIN Co., Ltd. and changed its name to It'S Hanbul Co., Ltd. in 2…
Full company profileIt's Skin Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
It's Skin Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 267B | 246B | 214B | 204B | 146B | 140B | 131B | 135B | 142B | 153B | 185B |
| Gross Profit | 164B | 155B | 130B | 114B | 79.0B | 76.3B | 73.4B | 77.8B | 94.6B | 102B | 124B |
| Operating Income | 73.3B | 45.4B | 19.9B | 10.9B | 3.76B | 755M | 4.81B | 11.2B | 17.9B | 19.2B | 28.3B |
| EBITDA | - | 58.1B | 27.4B | 24.0B | 11.4B | 12.3B | 16.3B | 28.0B | 46.9B | 41.8B | 72.0B |
| Net Income | 58.3B | 27.5B | 8.24B | -4.72B | -14.2B | -17.4B | -6.82B | 3.40B | 16.5B | 16.7B | 38.1B |
| EPS | - | 1,561 | 468 | -268 | -807 | -990 | -387 | 193 | 937 | 949 | 2,161 |
| Balance Sheet | |||||||||||
| Total Assets | 369B | 562B | 536B | 539B | 508B | 495B | 486B | 499B | 516B | 536B | 551B |
| Total Liabilities | 29.1B | 93.1B | 60.8B | 63.7B | 39.8B | 36.2B | 30.2B | 31.9B | 28.6B | 29.4B | 30.5B |
| Shareholders' Equity | 340B | 437B | 435B | 412B | 396B | 379B | 369B | 369B | 379B | 390B | 403B |
| Cash & Short-term Investments | 41.5B | 53.0B | 26.0B | 19.1B | 49.3B | 19.2B | 26.6B | 23.1B | 32.5B | 39.7B | 43.5B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 41.4B | 28.5B | 3.87B | 19.8B | 13.4B | 11.2B | 7.09B | 18.6B | 23.5B | 28.1B | 9.87B |
| Capital Expenditure | 6.84B | 12.2B | 6.86B | 10.4B | 1.98B | 871M | 1.40B | 4.27B | 3.55B | 1.77B | 1.77B |
| Free Cash Flow | - | 16.2B | -3.49B | 13.4B | 10.7B | 9.92B | 5.69B | 14.3B | 19.9B | 26.3B | 8.10B |
| Ratios | |||||||||||
| ROE | 17.2% | 6.3% | 1.9% | -1.1% | -3.6% | -4.6% | -1.8% | 0.9% | 4.4% | 4.3% | 9.5% |
| ROA | 15.8% | 4.9% | 1.5% | -0.9% | -2.8% | -3.5% | -1.4% | 0.7% | 3.2% | 3.1% | 6.9% |
| Net Profit Margin | 21.8% | 11.2% | 3.8% | -2.3% | -9.7% | -12.4% | -5.2% | 2.5% | 11.6% | 10.9% | 20.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
It's Skin Co Ltd dividends
- Dividend yield
- 5.30%
- Forward dividend
- 275.00 KRW
- Payout ratio
- 60.0%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 10.0B | 569 | 60.0% |
| 2024 | KRW 6.22B | 353 | 37.6% |
| 2023 | KRW 5.98B | 339 | 176.0% |
| 2022 | KRW 6.86B | 389 | - |
| 2021 | KRW 4.86B | 276 | - |
| 2020 | KRW 5.34B | 303 | - |
| 2019 | KRW 5.74B | 326 | - |
| 2018 | KRW 13.0B | 735 | 157.2% |
| 2017 | KRW 13.7B | 778 | 49.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Apr 26, 2016.
Who owns It's Skin Co Ltd
- Insiders 61.59%
- Institutions 0.61%
- Public & others 37.80%
- Shares outstanding 17.6M
- Free float 4.11M
It's Skin Co Ltd company profile
- Company name
- It's Skin Co Ltd
- Ticker
- 226320.KO
- ISIN
- KR7226320000
- Exchange
- Korea Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 75
- Fiscal year end
- December
- Address
- 311, Hakdong-ro, Seoul, South Korea
- Phone
- 82 2 3450 0343
- Website
- itshanbul.com
About It's Skin Co Ltd
It'S Hanbul Co., Ltd. develops, manufactures, and sells cosmetics in South Korea and internationally. It offers skin care and makeup products; amino acid toners and ampoules; cleansers, moisturizers, and highlighters; skin hydration solutions; and deodorants under the IT'S SKIN, Flamel MD, Dixionist, Chasin' Rabbits, ICS, ATOPALM, Real Barrier, Derma:B, and ZEROID brands. The company was formerly known as It'S SKIN Co., Ltd. and changed its name to It'S Hanbul Co., Ltd. in 2017. It'S Hanbul Co., Ltd. was founded in 1989 and is headquartered in Seoul, South Korea.
It's Skin Co Ltd management
1- Mr. Jae-ok JangSenior MD & Director · born 1956